Strong Analyst Confidence in Compass Therapeutics (CMPX) Driven by CTX-10726 Advancement

With beardown three-month show and important upside potential, Compass Therapeutics, Inc. (NASDAQ:CMPX) secures a spot connected our database of the 12 blistery penny stocks to put successful close now.

A doc successful a laboratory overgarment holding a healthcare solution successful their hands.

On November 10, 2025, H.C. Wainwright’s Joseph Pantginis reiterated a “Buy” standing connected Compass Therapeutics, Inc. (NASDAQ:CMPX) with a $24 terms target. The company’s advancing pipeline, marked by the preclinical advancement of CTX-10726, gained the analyst’s confidence, who was peculiarly impressed with the bispecific antibody’s important potential. At SITC 2025, the cause demonstrated high-affinity people engagement and robust anti-tumor activity. The expert besides cited the molecule’s competitory borderline implicit agents specified arsenic ivonescimab and bevacizumab, reinforcing optimism arsenic its planned Phase 1 proceedings successful 2026 comes closer.

Meanwhile, Compass Therapeutics, Inc. (NASDAQ:CMPX) reported Q3 2025 results connected November 5. The currency equilibrium reached $220 cardinal by the extremity of Q3, which volition enactment operations done 2028. G&A expenses recorded a important increase, increasing from $8.6 cardinal successful Q3 2024 to $12.8 million. Management besides reiterated its expectations to present wide endurance (OS) and progression-free endurance (PFS) information for tovecimig successful precocious Q1 2026. This could perchance enactment the company’s archetypal BLA filing successful the 2nd fractional of 2026. At the aforesaid time, Compass reported encouraging results successful the Phase 1 survey of CTX-8371. The institution recorded a nett nonaccomplishment of $14.3 million, oregon $0.08 per share, for the quarter.

Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology company, develops antibody-based therapies targeting angiogenesis, immune activation, and tumor evasion pathways.

While we admit the imaginable of CMPX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Small-Cap Biotech Stocks to Buy According to Analysts and 11 Overlooked Tech Stocks to Invest In.

Disclosure: None.